Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
McKinsey
Baxter
Johnson and Johnson
McKesson

Last Updated: July 1, 2022

CLINICAL TRIALS PROFILE FOR NULYTELY-FLAVORED


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Nulytely-flavored

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00164151 ↗ A Comparison of the Efficacy and Safety of HalfLytely Vs Visicol Prior To Colonoscopy. Completed Braintree Laboratories Phase 3 2001-06-01 The objective of this study is to determine the efficacy and safety of HalfLytely as compared to Visicol as bowel preparations before colonoscopic examination.
NCT00164164 ↗ HalfLytely Bowel Prep System for Colonoscopy Completed Braintree Laboratories Phase 3 1999-08-01 The purpose of the this study was to compare the safety and efficacy of HalfLytely (2L NULYTELY + 20mg bisacodyl) to NULYTELY for preparation prior to colonoscopy.
NCT00425594 ↗ A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population Completed Braintree Laboratories Phase 4 2007-01-01 This randomized, parallel, multi-center, single-blind study is designed to compare the safety and efficacy of 3 bowel preparations in pediatric subjects scheduled to undergo a colonoscopy for a routinely accepted indication.
NCT00689026 ↗ Efficacy of Lubiprostone in Combination With Standard PEG Preparation Terminated Takeda Pharmaceuticals North America, Inc. N/A 2008-05-01 A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics.
NCT00689026 ↗ Efficacy of Lubiprostone in Combination With Standard PEG Preparation Terminated Augusta University N/A 2008-05-01 A large population-based study has shown diabetes to be an independent risk factor for colon cancer compared to the general population. Thus, the completion of an adequately prepped colonoscopy is requisite in providing diabetics with adequate colon cancer screening. Recent data has shown that diabetic patients have poorer response to bowel cleansing compared to non-diabetics (with a standard PEG prep, only 62% of diabetic patients had their colonoscopy preps rated as good or better vs. 97% of normal patients, p<0.001). This may be due to the fact that a majority of diabetic patients report constipation as a common gastrointestinal complaint. We postulate that lubiprostone (Amitiza), in combination with PEG, will have additional efficacy over standard PEG preparation, and provide optimal safe and effective colonic cleansing for diabetics.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Nulytely-flavored

Condition Name

Condition Name for Nulytely-flavored
Intervention Trials
Colonoscopy 4
Preparation for Colonoscopy 2
Bowel Preparation 1
Bowel Preparation for Colonoscopy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Nulytely-flavored
Intervention Trials
Diabetes Mellitus, Type 2 1
Diabetes Mellitus, Type 1 1
Diabetes Mellitus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Nulytely-flavored

Trials by Country

Trials by Country for Nulytely-flavored
Location Trials
United States 30
Mexico 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Nulytely-flavored
Location Trials
Illinois 3
Texas 3
Minnesota 2
Indiana 2
Massachusetts 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Nulytely-flavored

Clinical Trial Phase

Clinical Trial Phase for Nulytely-flavored
Clinical Trial Phase Trials
Phase 4 3
Phase 3 3
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Nulytely-flavored
Clinical Trial Phase Trials
Completed 8
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Nulytely-flavored

Sponsor Name

Sponsor Name for Nulytely-flavored
Sponsor Trials
Braintree Laboratories 3
Gastroenterology Services, Ltd. 2
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Nulytely-flavored
Sponsor Trials
Industry 6
Other 5
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Merck
McKinsey
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.